GlassScriptPhysician profile
David J Hass
NPI 1225177769
$172,748.84
in general payments reported to CMS, 2019-2025
29 companies · $7,429 in 2025
The $7,429 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $47K · 2021: $54K · 2022: $17K · 2023: $11K · 2024: $9,009 · 2025: $7,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $3,238 · Food and Beverage: $2,506 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,500.00 |
| Consulting Fee | $3,238.00 |
| Food and Beverage | $2,505.55 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $94,151.47 | 2021-2025 | Bravo, Pillcam, Beacon |
| Covidien LP | $73,583.84 | 2019-2020 | |
| Abbvie INC. | $1,342.16 | 2019-2025 | |
| Iterative Scopes, INC. | $1,238.00 | 2024 | Skout |
| Takeda Pharmaceuticals U.S.A., INC. | $444.96 | 2019-2025 | Entyvio, Eohilia |
| Ferring Pharmaceuticals INC. | $196.17 | 2019-2025 | Rebyota |
| Janssen Biotech, INC. | $189.59 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.74 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $147.13 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $125.54 | 2024-2025 | Sucraid, Sucraid |
| Vericel Corporation | $124.99 | 2022 | |
| Pfizer INC. | $118.66 | 2023-2025 | |
| Celgene Corporation | $112.60 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $101.15 | 2020-2025 | |
| Boston Scientific Corporation | $98.98 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $98.08 | 2025 | Conmed Biliary |
| Intercept Pharmaceuticals, INC. | $90.64 | 2021-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $62.98 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $54.61 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $47.73 | 2025 | Omvoh |
| Genzyme Corporation | $45.94 | 2023 | |
| Pentax of America, INC. | $36.12 | 2022-2023 | Pentax Medical |
| Madrigal Pharmaceuticals | $34.74 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $27.61 | 2025 | The Cologuard Plus Collection Kit |
| Allergan, INC. | $26.08 | 2019-2020 | |
| Braintree Laboratories, INC. | $24.98 | 2023 | Sutab |
| Portola Pharmaceuticals, LLC | $24.38 | 2020 | |
| Vivus LLC | $17.76 | 2025 | Pancreaze |
| Shionogi INC | $13.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.